Thyme Care Doubles to $2B on Cancer Navigation
Morgan Health led a $125 million Series E with Humana and CVS Health Ventures joining, as the Nashville company's oncology navigation service reached 135,000 actively treated patients.
Company intelligence
As of September 4, 2026, Thyme Care was last valued at $2 billion (September 2026 Series E) and has raised at least $220M in equity across 2 sourced funding rounds.
Thyme Care is a value-based cancer care company that works with health plans, employers and risk-bearing providers and takes on accountability for care quality, outcomes and total cost of care.[1] It combines a technology-enabled care team with integration into oncology practices to support patients through treatment.[1] The company was founded in 2020.[1] Its funding announcements are datelined Nashville, Tennessee.[1] As of September 2026, its services were available to more than 10.5 million people in all 50 states, and it managed more than $7 billion in oncology spending.[2] The company reports validated reductions of 5% to 10% in total cost of care.[2] Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital and a16z Bio + Health were among the participants.[2] Alongside the round it created a parent company, Thyme Companies, to build separate oncology businesses, starting with biosimilar adoption and clinical trial enrollment.[2]
Thyme Care says it is profitable and generating positive free cash flow.[2]
Is something wrong on this page?
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 4, 2026 | Series E | $125M | $2 billionpost-money | Morgan Healthunverified | CNBCPulse story |
| Jul 16, 2024 | Series C | $95M | — | — | statnews.com |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
In July 2024 it raised a $95 million Series C that included new investor Concord Health Partners and returning investors Town Hall Ventures, Andreessen Horowitz, Foresite Capital and CVS Health Ventures.[3] That round followed a $60 million Series B about a year earlier and brought total funding to $178 million.[3] A $97 million Series D in September 2025 added Morgan Health, Humana, Texas Oncology and Memorial Hermann Health System as investors and brought total capital raised to $275 million.[1] In September 2026 it raised more than $125 million in a Series E led by Morgan Health at a valuation above $2 billion.[2]
In September 2026 it raised more than $125 million in a Series E led by Morgan Health at a valuation above $2 billion.[2]
Co-founders Robin Shah and Dr. Bobby Green previously worked in community oncology practices and on national infrastructure at Flatiron Health and OneOncology.[1]
Thyme Care is a value-based cancer care company that works with health plans, employers and risk-bearing providers and takes on accountability for care quality, outcomes and total cost of care.[1]
Thyme Care has raised at least $220M in equity across 2 sourced funding rounds tracked by Value Add VC. The most recent was a $125M Series E in September 2026 at a $2 billion post-money valuation, reported by CNBC. Debt financing, tender offers and secondary sales are not counted.
Lead investors in Thyme Care's sourced funding rounds include Morgan Health. Per round: its September 2026 Series E was led by Morgan Health.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.